Pricing Log in Create free account

Aktis Oncology, Inc. (AKTS) vs Prime Medicine, Inc. (PRME)

Aktis Oncology, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Prime Medicine, Inc. are of similar size ($826.0M and $807.1M). Aktis Oncology, Inc. has the higher net margin (−782.0% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Aktis Oncology, Inc. leads on 10 and Prime Medicine, Inc. on 3.

Valuation

Metric AKTS PRME Biotechnology median
P/E n/m n/m 10.60
P/S 90.34 200.59 9.40
P/B 1.80 20.52 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 36.79 177.25 9.02
Earnings yield (264.93%) (23.95%) (32.88%)
Free cash flow yield (15.97%) (19.20%) (23.13%)

Profitability

Metric AKTS PRME Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (939.13%) (4,824.94%) 0.00%
Net margin (781.95%) (4,613.11%) 0.00%
Free cash flow margin (1,442.91%) (3,850.92%) 0.00%
Return on equity (34.45%) (373.29%) (51.96%)
Return on assets (22.22%) (71.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AKTS PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.76%
EPS growth (last fiscal year) (25.43%) 18.18% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.33 3.05 4.97
Net debt to EBITDA 2.95 0.88 1.01

Dividend

Metric AKTS PRME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AKTS PRME Biotechnology median
Market cap 825.95m 807.12m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack